Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCRγδ+ T cell large granular lymphocyte leukemia by Kallemeijn, M.J. (Martine) et al.
RESEARCH ARTICLE
Dysregulated signaling, proliferation and
apoptosis impact on the pathogenesis of
TCRγδ+ T cell large granular lymphocyte
leukemia
Martine J. Kallemeijn1, Dick de Ridder2, Joyce Schilperoord-Vermeulen1, Michèle Y. van
der Klift1, Yorick Sandberg1, Jacques J. M. van Dongen1, Anton W. Langerak1*
1 Laboratory of Medical Immunology, Department of Immunology, Erasmus Medical Center Rotterdam,
Rotterdam, The Netherlands, 2 Department of Bioinformatics, Wageningen University, Wageningen, The
Netherlands
* a.langerak@erasmusmc.nl
Abstract
TCRγδ+ T-LGL leukemia is a rare form of chronic mature T cell disorders in elderly, which is
generally characterized by a persistently enlarged CD3+CD57+TCRγδ+ large granular lym-
phocyte population in the peripheral blood with a monoclonal phenotype. Clinically, the dis-
ease is heterogeneous, most patients being largely asymptomatic, although neutropenia,
fatigue and B symptoms and underlying diseases such as autoimmune diseases or malig-
nancies are also often observed. The etiology of TCRγδ+ T-LGL proliferations is largely
unknown. Here, we aimed to investigate underlying molecular mechanisms of these rare
proliferations by performing gene expression profiling of TCRγδ+ T-LGL versus normal
TCRγδ+ T cell subsets. From our initial microarray dataset we observed that TCRγδ+ T-
LGL leukemia forms a separate group when compared with different healthy control TCRγδ
+ T cell subsets, correlating best with the healthy TemRA subset. The lowest correlation
was seen with the naive subset. Based on specific comparison between healthy control
cells and TCRγδ+ T-LGL leukemia cells we observed up-regulation of survival, proliferation
and hematopoietic system related genes, with a remarkable down-regulation of apoptotic
pathway genes. RQ-PCR validation of important genes representative for the dataset,
including apoptosis (XIAP, CASP1, BCLAF1 and CFLAR), proliferation/development (ID3)
and inflammation (CD28, CCR7, CX3CR1 and IFNG) processes largely confirmed the dys-
regulation in proliferation and apoptosis. Based on these expression data we conclude that
TCRγδ+ T-LGL leukemia is likely the result of an underlying aberrant molecular mecha-
nisms leading to increased proliferation and reduced apoptosis.
Introduction
T cell large granular lymphocytic (T-LGL) leukemia is a heterogeneous chronic mature T cell
neoplasia, which is recognized as a separate hematological disorder according to the World
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Health Organization (WHO) classification [1]. T-LGL leukemia originates from normal LGL
cells which comprise 10–15% of peripheral blood mononuclear cells (PBMCs) [2] and can be
subdivided into two major groups based on the type of T cell receptor (TCR): TCRαβ or
TCRγδ. The majority of T-LGL leukemia involves the TCRαβ+ CD8+ variant (80–90%), while
only a small part of the T-LGL leukemia has a TCRαβ+CD4+ (1–5%) or TCRγδ+ phenotype
(5%) [3,4]. TCRγδ+ T-LGL leukemia is a chronic and heterogeneous disorder, which in fact
comprises a spectrum–from lymphoproliferative disease to leukemia–and generally shows an
indolent disease course, affecting mostly elderly patients with an average age of 60 years [5–7].
Approximately one-third of the patients is asymptomatic at diagnosis [8,9]. Most clinical fea-
tures concern neutropenia, recurrent bacterial infections and B symptoms that are associated
with chronic leukemia. Typically, TCRγδ+ T-LGL leukemia is highly associated with cytope-
nia, autoimmune diseases such as rheumatoid arthritis, and malignancies varying from other
hematological cancers to solid tumors [4]. The diagnosis is based on a persistent (>6 months)
monoclonal CD3+/CD57+/TCRγδ+ LGL population (>0.4 x 109/L) in the peripheral blood
(PB) and/or bone marrow (BM), confirmed by flow cytometry or cell morphology [9]. Fur-
thermore, TCRγδ+ T-LGL leukemia is mostly CD4-negative, partly CD8-positive, and approx-
imately 50% show CD16 and CD56 expression [6]. Despite recent advances for T-LGL
leukemia in general, the disease etiology of TCRγδ+ T-LGL leukemia remains largely
unknown. It has been hypothesized that chronic (antigenic) stimulation would play a major
role in the development of the proliferation, as has actually been shown for the TCRαβ+CD4
+ T-LGL leukemia type [10]. Also, in 2006 Sandberg et al. identified the presence of the so-
called invariant T selection determinant leading to a conserved amino acid at the relative sec-
ond position of the CDR3 region in Vδ2 –Jδ1 rearrangements in a large subgroup of TCRγδ
+ T-LGL proliferations, indicating that these cells are antigen-experienced. Furthermore, an
activation-associated effector phenotype and a skewed and dynamic TCR repertoire–also
referred to as clonal drift [11]–have been found in T-LGL proliferations, again suggestive of a
role for antigens, but the exact antigen or the type of antigens have so far not been elucidated
[3,12]. Even though the involved antigen(s) are unknown and might be variable, and the dis-
ease is clinically heterogeneous, we hypothesized that TCRγδ+ T-LGL leukemia patients have
common underlying molecular defects that contribute to the leukemogenesis. In order to
obtain more in-depth insights into the mechanisms driving these TCRγδ+ T-LGL prolifera-
tions we therefore performed gene expression profiling analysis in purified TCRγδ+ T-LGL
leukemia samples. Here we present data that TCRγδ+ T-LGL leukemia cells originate from the
most common antigen-experienced TCRγδ+ T cell population in the adult peripheral blood,
and that they have undergone a transformation leading to an imbalance in proliferation and
apoptosis, eventually contributing to the TCRγδ+ T-LGL leukemia pathogenesis.
Materials and methods
Patients and healthy controls
The database files from the department of Immunology, Erasmus MC, University Medical
Center (Rotterdam, The Netherlands) were retrospectively reviewed for cases with a proven
mature persistent (>6 months) TCRγδ+ T cell proliferation in PB and/or BM based on a com-
bination of clinical, histological (HE sections), cytomorphological (May-Gru¨nwald-Giemsa
staining), laboratory, immunophenotypical (including for the majority of cases most of the fol-
lowing markers: CD3, TCRγδ, CD4, CD8, CD16, CD56, CD57, CD45RA, CD45RO, CD27,
CD197) and molecular data (monoclonal TRG and TRD gene rearrangements) [13,14]. Other
TCRγδ+ T cell proliferation diseases such as hepatosplenic lymphomas were excluded based
on clinical, cytomorphological and/or histopathological data. From 10 TCRγδ+ T-LGL
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leukemia cases frozen cell material was available for inclusion in the current study. The immu-
nophenotypical and molecular analyses were performed on PB and/or BM samples which
were erythrocyte-lysed using FACS lysing solution (BD Biosciences, San Jose, CA, USA). PB-
or BMMC were isolated by means of Ficoll-Paque (density 1.077 g/ml, Pharmacia, Uppsala,
Sweden). As controls, healthy blood donors from Sanquin Blood Bank (Amsterdam, The
Netherlands) were included upon informed consent, which were anonymized for further use.
PBMCs were obtained with Ficoll density gradient separation and cryopreserved in Iscove’s
Modified Dulbecco’s Medium (IMDM, Lonza, Basel, Switzerland) with dimethyl sulfoxide and
stored in vials at -180˚C until further use.
Use of all samples for the study was approved by the Erasmus MC Medical Ethics Commit-
tee (MEC-2015-617). Studies were conducted in accordance with the principles of the Declara-
tion of Helsinki.
Immunophenotyping and cell sorting
Control PB samples were immunophenotyped to examine the composition of TCRγδ+ T cell
subsets based on membrane marker expression, including CD3, CD4, CD8, CD19, CD27,
CD45RA, CD45RO, CD27, CD197, TCRαβ, TCRVδ1 and TCRVδ2 (S1 Table). Measurements
were performed with a FACS Canto II or FACS LSR Fortessa flow cytometer (BD Biosciences).
The immunophenotype of the LGL proliferations was already determined during diagnostic
work-up, and was therefore available in the database.
For sorting experiments cryopreserved PB- and/or BMMCs were thawed and sorted. Sort-
ing was performed specifically on the tumor cells from the patient samples, using CD3, CD45,
TCRαβ, TCRγδ, TCRVδ1 and TCRVδ2 markers.
Healthy control samples were sorted into five different CD3+TCRγδ+ T cell subsets based
on gating strategies in S1 Fig: total TCRVδ1, total TCRVδ2, effector memory (= TemRO popu-
lation, CD45RO+CD27-CD197-), effector (= TemRA population, CD45RA+CD27-CD197-)
subsets and a naive, non-antigen stimulated control (CD45RA+CD27+CD197+) subset. Sort-
ing was performed with a FACS Aria I or III (BD Biosciences).
RNA isolation, cDNA synthesis
After sorting the cells were lysed and subjected to combined DNA/ RNA isolation with the
QIAGEN DNA/RNA/miRNA AllPrepKit (QIAGEN, Hilden, Germany).
For the gene expression profiling experiments RNA from the sorted healthy control TCRγδ
+ T cell subsets was pooled in order to obtain higher amounts of RNA and to create pooled
healthy control subset samples; N = 3 for Vδ1 and Vδ2 subsets, N = 8 for naive, TemRO and
TemRA subsets due to lower sorting yields.
For RQ-PCR tests cDNA was synthesized from isolated RNA as well as cryopreserved RNA
with reverse transcriptase Superscript II (Invitrogen Life Technologies, Waltham, MA, USA),
10x CA buffer (0.2 M Tris pH 8.3, 0.5M KCl), dNTP (GE Healthcare, Cleveland, OH, USA),
dithiotreitol (Invitrogen Life Technologies), MgCl2 (Applied Biosystems Life Technologies,
Waltham, MA, USA), recombinant RNAsin (Promega, Fitchburg, WI, USA) and random
primers (Invitrogen Life Technologies).
Gene expression profiling
Isolated RNA from sorted patient tumor cells and the 5 control TCRγδ+ T cell subsets was fur-
ther amplified, reverse transcribed into cDNA, purified, fragmented, biotinylated and hybrid-
ized to Affymetrix HG-U133 Plus 2.0 GeneChip arrays (containing 54,675 probe sets)
according to the Affymetrix GeneChip 3’ IVT Express Kit user manual (Affymetrix, Santa
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Clara, CA, USA), as described previously [15–17]. Robust multi-array average (RMA) back-
ground removal, compensation for systematic technical differences, quantile normalization
and probe set summary were performed [18]. Unsupervised correlation and clustering plots
were made based on selected probe sets that showed signal, i.e. for which the median absolute
deviation (MAD) from the median exceeded a certain threshold Thr on a log2 scale. To further
assess differential expression, a number of supervised analyses were applied: fold change calcu-
lation (FC), analysis of variance (ANOVA) [19] and significance analysis of microarrays
(SAM) were applied [20]. All comparisons concerned disease cases versus normal control
cases. Data were analyzed through the use of the Database for Annotation, Visualization, and
Integrated Discovery (DAVID Database) [21,22], and QIAGEN’s Ingenuity Pathway Analysis
(IPA, QIAGEN, Redwood City, USA; www.qiagen.com/ingenuity).
Real-time Quantitative PCR (RQ-PCR)
Assays were designed with the Roche Universal Probe Library (Roche, Basel, Switzerland) (S2
Table). RQ-PCR experiments were performed with TaqMan Universal PCR master mix (2x)
(Applied Biosystems) on the StepOnePlus instrument (Thermo Fisher, Waltham, MA, USA).
Ct values of disease samples were normalized to the Ct value of the ABL housekeeping gene
[23] and normalized Ct values of healthy control samples (ΔΔCt method).
Statistical analysis
Supervised statistical analyses for the gene expression profiling data were performed using
analysis of variance (ANOVA), with significance cutoff at p<0.05 and as threshold of up- and/
or down-regulation2 fold change. Significance of microarray analysis (SAM) with signifi-
cance cutoff <0.05 was included in the analysis as comparison. Bonferroni and Benjamini-
Hochberg p-value adjustment were applied for multiple testing correction and comparison of
different statistical tests on the data set.
Results
Heterogeneity in clinical presentation, associated diseases and
immunophenotype and–genotype among TCRγδ+ T-LGL leukemia
patients
In all ten patients a proven TCRγδ+ T-LGL leukemia was identified, based on immunopheno-
type, immunogenotype, high leukocyte count, and high percentage of TCRγδ+ T-LGL cells
compared with reference values of PB TCRγδ+ T cells (<5% of all lymphocytes in general) [6].
All cases were diagnosed as TCRγδ+ T-LGL leukemia, while other causes of TCRγδ+ T-cell
proliferation, such as hepatosplenic lymphoma, were excluded. There was a slight male pre-
dominance among the patients (seven males, three females). Most patients showed chronic
leukemia-associated symptoms, such as fever and cytopenia, and underlying (auto)immune
diseases such as rheumatoid arthritis, Graves’ disease and uveitis (Table 1). In general, immu-
nophenotyping showed CD3-positivity, CD4-negativity and in some cases CD8-positivity,
together with variable expression of markers that have been associated with LGL cells such as
CD16, CD56 and/or CD57, and frequent CD45RA positivity in combination with CD27 and/
or CD197 negativity, pointing towards TemRA and TemRO phenotypes (Table 1). For some
patients Vγ and Vδ-usage was determined with flow cytometry as well, which correlated with
the immunogenotyping data (Table 1). Among the patients half showed Vδ1 –Jδ1 rearrange-
ments, whereas the other half showed Vδ2 –Jδ1 rearrangements. Most patients had a Vγ9 –
Jγ1.1/2.1 or Jγ1.3/2.3 rearrangement, leading to an overall receptor predominance of Vγ9/Vδ1
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and Vγ9/Vδ2. Most patients showed a monoclonal TCRγδ+ T-LGL cell population at the
receptor level, whereas two patients showed a somewhat oligoclonal profile albeit with a domi-
nant clone, possibly indicating the presence of additional non-aberrant TCRγδ+ T cells or sub-
clones (Table 1).
Unsupervised clustering of TCRγδ+ T-LGL leukemia cases shows
highest resemblance to normal effector TCRγδ+ T cells
Despite some level of phenotypical heterogeneity between patients, we next evaluated the tran-
scriptomes of ten TCRγδ+ T-LGL leukemia patients versus five healthy control TCRγδ+ T cell
subsets in order to obtain more insight into the immunobiology of the disease and to possibly
identify common downstream pathogenic events in TCRγδ+ T-LGL leukemia. As from litera-
ture it is known that TCRγδ+ T-LGL leukemias are antigen-experienced [4,6], TemRO and
TemRA TCRγδ+ subsets were used as healthy control counterparts for the TCRγδ+ T-LGL
cells. As a non-antigen stimulated control the naive TCRγδ+ population was included. In
order to get a general view from gene expression profiling, first a correlation analysis was per-
formed based on selected probe sets that showed significant variation between all microarrays
(with a median absolute deviation from the median (MAD) of at least Thr = 0.7). In the heat-
map TCRγδ+ T-LGL leukemia cases and healthy control TCRγδ+ T cell subsets were on pur-
pose represented separately, as they represent distinct groups. The heatmap showed a clear
distinction between TCRγδ+ T-LGL leukemia cases and healthy control TCRγδ+ T cell sub-
sets, suggesting that the TCRγδ+ T-LGL leukemia cases indeed form a separate group with a
distinct transcriptome (Fig 1A). The healthy control subset that correlated best with the
TCRγδ+ T-LGL leukemia cases was the TemRA TCRγδ+ T cell subset, and to a lesser extent
the TemRO subset, in line with our patient phenotype data (Table 1), whereas the naive
TCRγδ+ T cell subsets showed the lowest correlation, as was expected (Fig 1B). Hierarchical
clustering confirmed that 8/10 TCRγδ+ T-LGL leukemia cases indeed formed a separate group
from the healthy control subsets, whilst two cases, LGL087 and LGL113, grouped together
with TemRA, TemRO and TCRVδ2 subsets (Fig 1C). The same clustering was observed when
a principal component analysis (PCA) was performed (Fig 1D). One case was studied in duplo
(LGL058, Fig 1) to assess reproducibility of the arrays, which was indeed high. Overall the
TCRγδ+ T-LGL leukemia cases thus mostly form a separate group based on their gene expres-
sion profile, showing closest correlation with the healthy normal TemRA TCRγδ+ T cell
subset.
Supervised analysis showed a dysregulated balance in proliferation and
apoptosis
Following unsupervised clustering analysis, specific comparisons were performed between all
TCRγδ+ T-LGL leukemia cases vs. naive, TemRO and TemRA healthy control TCRγδ+ T cell
subsets. Two statistical comparisons, significance analysis of microarrays (SAM) and two-way
analysis of variance (ANOVA) were applied that yielded varying numbers of differentially
expressed probe sets (S3 Table). Stringent statistical filtering using SAM showed low numbers
of mainly down-regulated genes in the comparison between TCRγδ+ T-LGL leukemia cases
and TemRO and TemRA subsets. When the comparison was performed with the naive subset,
the numbers of differentially expressed probe sets found by both statistical analysis methods
were high. Both methods confirmed the relatively high similarity of TCRγδ+ T-LGL leukemia
cases to the healthy TemRO and TemRA subsets, and the lower similarity to naive TCRγδ+ T
cells as also observed in the unsupervised clustering. Since the SAM analysis showed low num-
bers of differentially expressed probe sets, and in order to reduce the risk of missing data, we
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therefore used the two-way ANOVA set for further supervised analysis. Top up- and down-
regulated genes in TCRγδ+ T-LGL leukemia cells vs. the best correlating subset, the TemRA
TCRγδ+ T cells, are depicted in S4 Table. Most up-regulated genes appeared to be involved in
the inflammatory response and response to bacteria: LYZ, S100A8, S100A9,ALOX5 and LTB
according to the DAVID database. The top down-regulated genes were mostly associated
with the process of transcription; these genes included amongst others GTF2H3,CTBP2 and
ZNF260.
In order to identify genes associated with biologically more relevant pathways and pro-
cesses, the probe sets that were significantly differentially expressed with a fold change of at
least 2 (both up- and down-regulated) in TCRγδ+ T-LGL leukemia cells when compared to
the healthy TemRA TCRγδ+ T cell subset were then further analyzed with the DAVID data-
base [21,22]. Gene Ontology biological process analysis showed processes involved in the
Fig 1. Unsupervised gene expression data analysis. (A) Heatmap analysis shows clear correlations between TCRγδ+ T-LGL
proliferation cases, and lower correlations to the healthy control TCRγδ+ T cell subsets, (B) the highest being to the TemRA TCRγδ+ T cell
subset. (C) The clustergram shows that the TCRγδ+ T-LGL proliferation cases indeed form a distinct group, except for two cases which
cluster closer to healthy control TemRA, TemRO and TCRVδ2 TCRγδ+ T cell subsets. (D) Principal component analysis (PCA) in three-
dimensional (3D) graph shows similar clustering results. Thr = 0.7; 1336 probe sets. Case LGL058 indicated in italics was studied in duplo to
assess reproducibility of the assay.
https://doi.org/10.1371/journal.pone.0175670.g001
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regulation of the immune system and response, T cell activation, and response to stress to be
affected (Table 2). Enrichment analysis of KEGG pathways in DAVID showed that differen-
tially expressed genes were largely involved in the hematopoietic cell lineage, osteoclast differ-
entiation, rheumatoid arthritis disease and NFκB signaling, although after correction for
multiple testing none of these were found to be significant. Nevertheless, similar processes,
such as hematopoietic system and inflammation, were identified (Table 3). Differentially
expressed probe sets in the comparison between TCRγδ+ T-LGL leukemia cells vs. TemRO
cells showed similar processes to be affected (S5 Table). Taken together, both annotation
enrichment analyses (Gene Ontology, KEGG) indicated that proliferation, cell survival signal-
ing and inflammatory processes were affected.
For further interpretation and visualization of differentially expressed genes, Ingenuity
Pathway Analysis (IPA) was used. First, TCRγδ+ T-LGL leukemia cases were compared to
healthy TemRA TCRγδ+ T cells, showing a number of processes which were up-regulated in
the TCRγδ+ T-LGL leukemia cases, such as hematological development and function. How-
ever, cell death and survival processes appeared to be significantly down-regulated (Fig 2A).
Again, similar results were obtained after analyzing the differentially expressed probe sets
between TCRγδ+ T-LGL leukemia cases and the healthy TemRO subset (Fig 2B), confirming
comparable correlation of both subsets with the TCRγδ+ T-LGL leukemias as described from
the unsupervised analysis (Fig 1).
After identifying affected processes we focused more in-depth on specific genes. Genes
involved in apoptosis, such as BCLAF1,CASP1, XIAP and CFLAR, appeared to be the most rel-
evant candidate genes. The apoptosis-inducing genes CASP1 and CFLARwere down-regu-
lated, as well as the apoptosis inhibitor XIAP, while BCLAF1was up-regulated. Furthermore,
transcription factors such as ID3, KLF4, LEF1 and SOX4 in the up-regulated cell survival pro-
cess were all found to be up-regulated. Finally, altered expressions of CD28,CCR7,CX3CR1,
IFNG, LTB and PRF1 were all contributing to the inflammatory profile of the TCRγδ+ T-LGL
leukemias.
Collectively, data from all analysis methods (DAVID Gene Ontology, DAVID KEGG, IPA)
thus showed that proliferation and cell survival signaling were up-regulated, while apoptosis
was down-regulated in TCRγδ+ T-LGL leukemia cells when compared to normal TCRγδ+ T
cell subsets.
RQ-PCR validation indicates possible signature genes within a highly
heterogeneous disease profile
Next, representative candidate genes, which were found in the comparison between TCRγδ
+ T-LGL leukemia cells and healthy TemRA and TemRO TCRγδ+ T cells in both IPA and
DAVID analysis, and which appeared biologically relevant for the disease, were selected. These
included genes involved in cell death and survival processes (BCLAF1,CFLAR,CASP1, and
XIAP), genes associated with proliferation-driving transcription or cancer (KLF4, LEF1, SOX4,
ID3), and genes associated with inflammation (CD28,CCR7,CX3CR1 and IFNG). Differences
in gene expression levels were analyzed by means of real-time quantitative (RQ)-PCR using
Universal Probe Library reagents. Sorted healthy control TemRA TCRγδ+ T cells were com-
pared with the sorted TCRγδ+ T-LGL leukemia cells from patients (both from patients
included in the microarray analysis, and from new patients). In order to validate the fold
changes obtained from microarray analysis, expression ratios between patients and healthy
controls were calculated from the RQ-PCR data. All selected apoptosis-related genes from our
microarray analysis, were confirmed to be differentially expressed in TCRγδ+ T-LGL leukemia
cases when compared to healthy controls; XIAP, CASP1, BCLAF1were all validated to be over
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Table 2. Gene ontology biological process annotation analysis of TCRγδ+ T-LGL leukemia cases versus healthy TCRγδ+ TemRA cells in DAVID.
Term Gene
count*
Genes p-
value
Bonferroni** Benjamini**
Immune response 138 A.o.: BTK, CCL4, CCR7, CXCL16, CXCL8, CXCR5, CX3CR1, CLEC7A, CD14,
CD1D, CD226, CD28, CD36, CD3D, CD58, CD79A, CD86, CD8B, CRK, FYN,
FAS, FCER genes, JAK3, MYB, NLRP3, RAB29, REL, S100 genes, TAB2, XIAP,
XAF1, AIF1, APOBEC genes, BTN3A3, CAMK4, CR1, CR2, C5AR1, CFP, CYBB,
DLL1, EGR1, FCN1, FOXP1, HSP genes, HAVCR2, IFIT, IRF, IRAK2, IL23A,
IL27RA, IL6R, KLRD1, LILRA genes, LY86, LY96, LEF1, LTB, HLA-DRA,
HLA-DRB4, MAPK1, MAP3K1, NCF, NFKB, PRF1, PIK3R1, PF4, PARP9,
STAT1, TLR2, TFEB, TRIM genes, TNFSF13B, TNFSF8
3.9E-
19
2.5E-15 2.5E-15
Defense response 129 A.o.: ALS2, ANKHD, APOBEC genes, BTK, CCL4, CCR7, CXCL16, CX3CR1,
CLEC7A, CD14, CD1D, CD226, CD28, CD36, CD58, CD86, CD8B, DDX3X,
DDX60, FYN, FAS, FCER genes, IFI30, JAK3, KLF4, NLRP3, PRDM1, REL, S100
genes, TAB2, XIAP, XAF1, AIF1, ALOX5, CAMK4, CASP1, CSF3R, CR1, CR2,
C5AR1, CFD, CFP, CST3, CYBB, EGR1, FCN1, FOXP1, FPR1, GFI1, HSP
genes, HAVCR2, IG genes, IFNGR2, IFNG, IFIT genes, IRF genes, IL23A,
IL27RA, IL6R, KLRD1, LILRA genes, LY genes, LYZ, HLA-DRA, HLA-DRB4, NCF
genes, NFKB genes, PRF1, STAT1, TLR2
5.3E-
13
3.4E-9 1.1E-9
Cell activation 87 A.o.: ABAT, ADAM10, BTK, CCR7, CXCL8, CXCR5, CX3CR1, CLEC7A, CD1D,
CD2, CD226, CD28, CD3D, CD5, CD79A, CD86, CD8B, LIG4, FYN, FAS, FCER
genes, JAK3, MAFB, MYB, NLRP3, SOX4, CAMK4, CR2, CST3, DLL1, EGR1,
FOXP1, HAVCR2, IRS2, IFNG, IRF1, IL23A, IL27RA, IL6ST, LEF1, HLA-DRA,
HLA-DRB4, PRF1, PIK3R1, PF4, SLAMF1, TLR2, TNFSF13B, TNFSF8, VCL
4.9E-
12
3.2E-8 6.3E-9
Regulation of immune
system process
116 A.o.: ADAM10, BTK, CCL4, CCR7, CXCL8, CLEC7A, CD14, CD1D, CD2, CD226,
CD28, CD36, CD3D, CD5, CD79A, CD86, CD8B, CRK, DDX60, FYN, FANCL,
FAS, FCER genes, JAK3, MAFB, MYB, RAB29, TAB2, XIAP, AIF1, CSF3R, CR1,
CR2, CFD, CFP, DLL1, FCN1, FOXP1, FPR1, HSP genes, HAVCR2, IFNGR2,
IFNG, IFIT1, IRF1, IRAK2, IL23A, IL27RA, IL6R, KLRD1, LILRB genes, LEF1,
HLA-DRA, HLA-DRB4, MAPK1, MAP3K1, NFKB1, PIK3R1, PARP9, SLAMF1,
TLR2, TNFSF13B, VEGFA
2.5E-
11
1.6E-7 2.3E-8
Leukocyte activation 74 A.o.: ADAM10, BTK, CCR7, CXCL8, CXCR5, CX3CR1, CLEC7A, CD1D, CD2,
CD226, CD28, CD3D, CD5, CD79A, CD86, CD8B, LIG4, FYN, FAS, JAK3, MAFB,
MYB, RAB29, AIF1, SOX4, DLL1, FOXP1, HAVCR2, IRS2, IFNG, IRF1, IL23A,
IL27RA, IL6ST, LEF1, HLA-DRA, HLA-DRB4, PRF1, PIK3R1,
3.9E-
11
2.5E-7 3.2E-8
Response to stress 238 A.o.: ABAT, ALS2, APC, APOBEC genes, BTK, BCLAF1, CCL4, CCR7, CXCL16,
CXCL8, CX3CR1, CLEC7A, CFLAR, CD14, CD1D, CD226, CD28, CD36, CD58,
CD86, CD8B, DDX3X, DDX60, LIG4, POLH, FYN, FANCL, FANCM, FAS, JAK3,
KLF4, MAFF, NLRP3, PRDM1, REL, S100 genes, SOX4, TIAM1, TAB2, XIAP,
XAF1, ALOX5, CASP1, CDC7, CSF3R, CR1, CR2, C5AR1, CFD, CFP, EGR1,
FCN1, FOXP1, FPR1, HSP genes, HAVCR2, ID3, IFNGR2, IFNG, IFIT genes,
IRF1, IRF2, IL23A, IL27RA, IL6ST, LILRA genes, LYZ, HLA-DRA, HLA-DRB4,
NCF genes, NFKB genes, PARP9, STAT1, SLAMF1, PIK3R1, PRF1, USP genes,
VEGFA, TNFSF8
6.0E-
11
3.8E-7 44.3E-8
Cytokine production 65 A.o.: BTK, CCR7, CD14, CD2, CD226, CD28, CD36, CD58, CD86, DDX3X,
DDX60, JAK3, KLF4, MAF, NLRP3, REL, S100 genes, TIA1, CAMK4, CASP1,
CYBB, DLL1, EGR1, FCN1, FOXP1, GBP1, HSP genes, HAVCR2, IFI16, IFNG,
IRF1, IL23A, IL27RA, IL6R, IL6ST, LEF1, LY96, LTB, NFKB1, NFKB2,
HLA-DRB4, PF4, SLAMF1, TLR2
2.3E-
10
1.5E-6 1.5E-7
T cell activation 50 A.o.: CCR7, CLEC7A, CD1D, CD2, CD28, CD3D, CD5, CD85, CD8B, LIG4,FYN,
FAS, FCER1G, JAK3, MAFB, MYB, NLRP3, PRDM1, RAB29, SOX4, AIF1,
BATF1, CAMK4, EGR1, FOXP1, HAVCR2, ITPKB, IFNG, IFR1, IL23A, IL6ST,
LEF1, HLA-DRA, HLA-DRB4, PIK3R1, PRNP, RHOH, SLAMF1, TNFSF13B,
TNFSF8
3.6E-9 2.3E-5 1.2E-6
*Total 1024 differentially expressed genes in LGL versus TemRA dataset with FC = 2 both up- and down-regulated, p<0.05 (ANOVA), of which 805 were
annotated by DAVID using Affymetrix Human Genome U133 Plus 2.0 array as background and selecting Homo Sapiens as species.
**Adjusted p-value based on Bonferroni and Benjamini-Hochberg correction for multiple testing.
Genes also identified through IPA analyses, which are further validated with RQ-PCR are indicated in bold.
https://doi.org/10.1371/journal.pone.0175670.t002
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two-fold higher, and especially CFLAR to an even higher extent than observed in the microar-
rays (Fig 3). Transcription factor ID3 could also be validated in RQ-PCR; the ratio between
TCRγδ+ T-LGL leukemia patients and healthy controls was even higher than that observed in
the microarrays. Other transcription factors identified from the microarray analysis (KLF4,
LEF1 and SOX4) could not be confirmed by RQ-PCR validation (S6 Table). CD28,CCR7 and
CX3CR1were validated as well, albeit with a lower fold change than in the microarrays. IFNG
was validated with an approximately two-fold higher fold change in RQ-PCR than in the
microarrays (Fig 3). Of note, considerable heterogeneity in RQ-PCR levels was observed
within the samples used for validation (S6 Table), thus reflecting the heterogeneity of the
disease.
Taken together, we were able to identify possible candidate genes to distinguish aberrant
from normal TCRγδ+ T cells, although the known largely heterogeneous profile of the disease
remains noticeable, which may partly mask differences between leukemic TCRγδ+ T-LGL
cells and normal TCRγδ+ T cell subsets.
Discussion
T cell large granular lymphocyte disorders form a large group of heterogeneous mature T cell
neoplasms, of which the TCRγδ+ T cell variant is rare and most poorly understood. TCRγδ
+ T-LGL leukemia is known to have a slowly progressive indolent disease course, mostly
affecting elderly individuals, while showing similar (initial) clinical presentations such as neu-
tropenia, anemia and pancytopenia [4,6,25]. Most of our patients displayed malignancy, auto-
immunity or cytopenia as underlying or associated diseases, as described previously [26], but
there was no consistent pattern. Furthermore, immunophenotypic features did not correlate
with the symptomatic status or underlying diseases. Underlying (chronic) diseases could play
a role in the pathogenesis of TCRγδ+ T-LGL leukemia, possibly as a (chronic) stimulus that
causes the TCRγδ+ T cells to expand, in line with the idea that TCRγδ+ T-LGL leukemia
develops from dominant normal TCRγδ+ T cell populations in the adult peripheral blood.
Table 3. KEGG enrichment pathway analysis of TCRγδ+ T-LGL leukemia cases versus healthy TCRγδ
+ TemRA cells in DAVID.
Term Gene
count
Genes p-
value
Bonferroni* Benjamini*
Hematopoietic cell
lineage
16 CD14, CD1d, CD2, CD36, CD3d,
CD5, CD8b, ANPEP, CSF3R, CR1,
CR2, ITGA6, IL6R, HLA-DRA,
HLA-DRB, MS4A1
1.3E-
5
3.3E-3 3.3E-3
Osteoclast
differentiation
19 BTK, FYN, TAB2, CAMK4, CYBB,
IFNGR2, IFNG, LILRA/LILRB genes,
NCF1, NCF2, NFKB1, NFKB2,
PIK3R1, SIRPA, STAT1
9.9E-
5
2.6E-2 1.3E-2
Rheumatoid
arthritis
13 ATP6V genes, CXCL8, CD28, CD86,
IFNG, IL23A, LTB, HLA-DRA,
HLA-DRB4, TLR2, TNFSF13B,
VEGFA
8.1E-
4
1.9E-1 5.2E-2
NF-kappa B
signaling pathway
13 BTK, CCL4, CXCL8, CFLAR, CD14,
TAB2, XIAP, LY96, LTB, NFKB1,
NFKB2, PIAS4, TNFSF13B
1.0E-
2
2.3E-1 5.1E-2
*Adjusted p-value based on Bonferroni and Benjamini-Hochberg corrections for multiple testing.
Genes also identified through IPA analyses, which are further validated with RQ-PCR, are indicated in bold.
https://doi.org/10.1371/journal.pone.0175670.t003
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However, underlying molecular mechanisms in TCRγδ+ T-LGL leukemogenesis are largely
unknown, and a common underlying molecular defect has not been described earlier.
TCRγδ+ T-LGL leukemias are characterized by skewed receptor expression and an antigen
stimulation-associated activation status, but are also considered to harbour particular changes
in gene expression. In our current study we aimed to address this by means of gene expression
profiling, which revealed that the TCRγδ+ T-LGL leukemia cells displayed different gene
expression profiles when compared to healthy, polyclonally expanded TCRγδ+ T cells. Initial
unsupervised clustering based on microarray data from aberrant TCRγδ+ T cells and different
healthy TCRγδ+ T cell subsets, showed a clear distinction between the TCRγδ+ T-LGL leuke-
mia and its healthy counterparts. Even though TCRγδ+ T-LGL leukemia forms a separate
group, with the lowest correlation with the naive subset as expected, the correlation with the
TemRA subset was quite high, suggesting that it is derived from the most predominant and
antigen-experienced type of TCRγδ+ T cell populations in adult peripheral blood, in line with
earlier published data [27]. When focusing more in-depth on differences in comparison with
normal TemRA TCRγδ+ T cells it became clear that particular biological functions, processes
and genes were affected. Most relevant genes involved processes such as proliferation,
Fig 2. Functional annotation of genes differentially expressed between TCRγδ+ T-LGL leukemia cases and healthy control TCRγδ+ T cell
subsets. (A) Comparison of TCRγδ+ T-LGL leukemia cases versus healthy control TemRA and (B) TemRO TCRγδ+ T cell subsets showing similar patterns
with down-regulation of apoptosis and up-regulation of cancer-related processes. Sizing based on significance level (ANOVA), up- and down-regulation
based on z-scoring. Plots were generated in QIAGEN’s Ingenuity Pathway Analysis.
https://doi.org/10.1371/journal.pone.0175670.g002
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stimulation and apoptosis, with an increase in proliferation and cell survival, and a decrease in
apoptosis. One clear example concerned transcription factor ID3, which is involved in prolifer-
ation and haematological development, a.o. by enhancing TCRγδ+ T cell development [28].
Up-regulation in TCRγδ+ T-LGL leukemia cases could be confirmed with RQ-PCR. As
opposed to proliferation genes, some apoptosis-inducing genes such as CASP1 and CFLAR
were down-regulated. Caspase-1 is an apoptosis-related cysteine peptidase, which is involved
in inflammation and apoptosis by proteolysis of pro-inflammatory cytokines and activating
other caspases and pro-apoptotic proteins [29,30]. CFLAR has been described in multiple stud-
ies as being important in the development of cancer, and is therefore also being described as a
target for therapy (reviewed by Fulda in 2013 [31]); it induces apoptosis [32], but is also a key
role player in autophagy and necroptosis [33]. XIAP, which normally regulates and inhibits
apoptosis [34] was also shown to be down-regulated, resulting in a net effect of inhibited apo-
ptosis. The up-regulated apoptosis-related gene BCLAF1 induces apoptosis and represses tran-
scription [35]. Our RQ-PCR validation data also showed up-regulation of BCLAF1, and down-
regulation of CFLAR and CASP1. All apoptosis-related genes could be confirmed with
RQ-PCR, thus showing consistency of these shared aberrancies in different TCRγδ+ T-LGL
leukemia patients. Interestingly, our data on TCRγδ+ T-LGL leukemia are thus completely in
line with earlier studies, showing signaling towards survival through positive regulation of T
cell receptor signaling and an enhanced immune response, rather than towards induction of
apoptosis [36,37]. Additionally, the supervised analysis yielded aberrancies in the normal
functioning of the TCRγδ+ T-LGL lymphoproliferative cells, with more skewing towards acti-
vation and inflammation given the up-regulation of CD28 and CCR7. IFNG on the other hand
was down-regulated, implying that normal functioning of TCRγδ+ T cells through IFN-γ
Fig 3. RQ-PCR validation of most representative genes. Fold changes of representative genes identified
through gene expression profiling and by RQ-PCR. Relative expression of genes found differentially
expressed using microarrays was first normalized to ABL housekeeping gene (ΔCt). Average ΔCt values from
healthy controls (N = 6) were used to calculate patient (N = 10) to healthy control ratios per patient to obtain
fold change values (ΔΔCt). White bars depict fold change values obtained from microarray data, grey bars
depict average ΔΔCt values after RQ-PCR validation. For RQ-PCR validation 4 patients from the original
microarray dataset were used and 6 novel patients. Mean expression fold change values are indicated with
the standard deviation.
https://doi.org/10.1371/journal.pone.0175670.g003
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production upon activation during infection [38], is lost. These expression levels were also
confirmed on fold change level by means of RQ-PCR. Furthermore, communication of the
TCRγδ+ T-LGL leukemia cells with other immune cells was affected as reflected by the down-
regulation of chemokine CX3CR1.
In CD8+ TCRαβ+ T-LGL leukemia altered signaling through STATs has been implicated
in the leukemogenesis, based on the frequent occurrence in mutations in the STAT3 and/or
STAT5b genes [39,40]. In our cohort of 10 TCRγδ+ T-LGL leukemia cases analyzed with gene
expression profiling we checked expression levels of STAT3 and STAT5b genes but did not
find significant alterations as compared to healthy control TCRγδ+ T cell subsets. This might
suggest that STAT3 and STAT5b are less clearly implicated in the pathogenesis of TCRγδ
+ T-LGL leukemia than CD8+TCRαβ+ T-LGL and/or NK-LGL leukemia. Furthermore, it has
been shown previously that the survival of leukemic T-LGL cells is rather through STAT3-in-
dependent signaling [36].
Notably, not all genes could be confirmed with the same fold change in microarrays and
RQ-PCR. High heterogeneity in expression levels within both healthy controls and patients
was observed. This could be due to general differences between individuals, displaying differ-
ent gene expression profiles, ranging from ones with high proliferative activity of TemRA
TCRγδ+ T cells, to ones with low activity. Therefore, a more extended investigation into the
aberrant apoptotic profile of a higher number of TCRγδ+ T-LGL leukemia patients is war-
ranted. Furthermore, stimulation of the TCRγδ+ T-LGL leukemia cells, or in vitro blocking of
the apoptotic genes identified and validated in our study, should provide more insights in the
activation profile or the activity against for instance other blood cells, which could potentially
explain the accompanying cytopenia as seen in these patients. Also, this could shed light on
the underlying stimulations of the TCRγδ+ T cells required for proliferation. Additionally,
novel techniques such as RNA-sequencing might be helpful in creating a broader perspective
on the disease, including more information about possible splice variants and single nucleotide
variants.
Conclusion
Overall, our current study provides more insight in the pathogenesis of TCRγδ+ T-LGL leuke-
mia by showing a disturbed balance in proliferation and apoptosis, but also in immune and
inflammatory responses and normal functioning of the TCRγδ+ T cells. TCRγδ+ T-LGL leu-
kemia cells originate from antigen-experienced normal TemRA/TemRO TCRγδ+ T cells in
adult peripheral blood, but these TCRγδ+ T-LGL cells have undergone a shift in the prolifera-
tion-apoptosis balance, towards increased proliferation and survival.
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